Supernus Pharmaceuticals Inc. (SUPN), a revenue-generating biopharmaceutical company developing medicines for the treatment of central nervous system diseases, has a regulatory catalyst to watch next month.
The FDA decision on SPN-830, the company's investigational apomorphine infusion device for the continuous treatment of motor fluctuations ("OFF" episodes) in Parkinson's disease, is expected on February 1, 2025.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.